BioSpace News Archive

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of RTX-240

Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada.

Datavant, the leader in helping healthcare organizations safely connect their data, and ZS, a leading global professional services firm, announced a strategic partnership enabling ZS to deploy Datavant’s technology on behalf of its clients.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Sustainable Health and Clean Beauty markets through its consumer brands and a top supplier of sustainably sourced natural ingredients, today announced financial results for its third quarter ended September 30, 2020.

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, today announced two abstracts have been selected for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting being held December 5-8, 2020.

Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs

Protomer Technologies Inc. (“Protomer”), the biopharmaceutical company today announces the completion of an investment by the JDRF T1D Fund following an initial equity investment in Protomer led by Eli Lilly and Company.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2020, and provided a business update.

Smith+Nephew, the global medical technology business, announces the addition of ARIA SiteSelect and ARIA Optimized Recovery Pathways to its digital episode of care management platform, ARIA.